Robert von Rosen is a partner in the Basel office of Walder Wyss. His practice focuses on domestic and international M&A transactions (mainly private M&A/private equity and venture capital) with a focus on telecommunication, energy and life sciences. In addition, he advises mainly medium-sized and start-up companies and SMEs on questions of corporate governance, compliance, restructuring and all other legal aspects of day-to-day business operations. Robert von Rosen is a board member of several corporations and foundations (e.g. Optiswiss Ltd, Holle baby food Ltd. GRS Wieland Foundation).

After completing an apprenticeship in banking, Robert von Rosen studied at the Albert-Ludwigs-University Freiburg, Germany (law exam 2004, bar exam 2006). During that time, he worked as scientific assistant at the professorship in civil law, industrial property protection and copyright law. Before joining Walder Wyss, Robert von Rosen worked for eight years at a leading Swiss law firm, supplemented by a secondment with the Swiss Financial Market Supervisory Authority FINMA.

Robert von Rosen practices in German and English. He is registered with the Basel bar registry and is also admitted to the bar in Germany.

Axalta Coating Systems Group acquires André Koch AG

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

CONVOTIS stärkt seine Position in der Schweiz durch die neueste Akquisition der acdalis AG, einem anerkannten Spezialisten für Managed Cloud und Infrastruktur Services.

Coopers acquires iET Group

IFLR 1000 Rankings - Walder Wyss as a top-performing law firm ranked

The Best Lawyers Awards 2024

GEODIS acquires ITS - International Transport & Shipping Ltd. and expands its freight forwarding offering in Switzerland

Datacolor acquires matchmycolor

PwC Switzerland acquires Avoras

Skribble AG completes Series A round of funding joins Elvaston

Elvaston sells Magnolia International AG to GENUI

Cawood acquires IES Ltd

proLogistik Holding GmbH acquisisce XELOG AG

Dr. Wild & Co. AG vende la sua attività farmaceutica a Verfora SA

Boehringer Ingelheim: 1,18 miliardi di euro per acquisire NBE Therapeutics

Round di finanziamento di serie A da CHF 54 milioni per Noema Pharma

Synendos Therapeutics CHF 20m Series A Financing

Round di finanziamento di serie B da CHF 19 milioni per BioVersys

Versant Ventures lancia Matterhorn Biosciences

ImmunOs Therapeutics AG raises CHF 15m in Series A Financing

Lindsay Goldberg acquisisce Bilcare Research Group

GrandVision rileva McOptic

Boehringer Ingelheim acquisisce Amal Therapeutics SA

Round di finanziamento da CHF 12,5 milioni per Alentis Therapeutics SA

NNIT A/S rileva Halfmann Goetsch Partner AG

Precision Surfacing Solutions acquista la divisione di Meyer Burger specializzata in wafer fotovoltaici

SHS investe nella società svizzera del settore Life Science evitria SA

Cellestia Biotech SA: round di finanziamento di serie A da CHF 20 milioni

BC Platforms CHF10 Mio. B Runde

RWS acquires LUZ, Inc.

Spadina House AG erwirbt SkyVision

Acino veräussert sein Geschäft mit transdermalen Pflastern an Luye Pharma Group Ltd.

Bayer und CRISPR Therapeutics gründen Genome Editing Joint Venture

Honeywell übernimmt Aviaso

Kauf und Refinanzierung der Boost Holding AG

Energiedienst Holding AG und TRITEC bündeln ihr Know-how

Avanade erwirbt

P&I Personal & Informatik AG übernimmt Geschäftsbereich HR der Soreco AG

SVC-AG für KMU Risikokapital erwirbt Minderheitsbeteiligung an Stratpharma AG

Kliniken Valens übernimmt Rheinburg-Klinik